Simvastatin - Generic Drug Details

What are the generic drug sources for simvastatin and what is the scope of freedom to operate?

Simvastatin is the generic ingredient in four branded drugs marketed by Salerno Pharms, Synthon Pharms, Accord Hlthcare, Aurobindo Pharma, Biocon Pharma, Chartwell Rx, Hetero Labs Ltd Iii, Invagen Pharms, Ivax Sub Teva Pharms, Lupin, Micro Labs, Oxford Pharms, Pharmobedient, Rising, Sun Pharm Inds Ltd, Watson Labs Teva, Yiling, Zydus Pharms Usa, Organon, and Merck Sharp Dohme, and is included in twenty NDAs. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Simvastatin has twelve patent family members in twelve countries.

There are forty drug master file entries for simvastatin. Twenty-nine suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for simvastatin

International Patents:	12
US Patents:	3
Tradenames:	4
Applicants:	20
NDAs:	20
Drug Master File Entries:	40
Finished Product Suppliers / Packagers:	29
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	601
Patent Applications:	6,072
Drug Prices:	Drug price trends for simvastatin
Drug Sales Revenues:	Drug sales revenues for simvastatin
What excipients (inactive ingredients) are in simvastatin?	simvastatin excipients list
DailyMed Link:	simvastatin at DailyMed

See drug prices for simvastatin

See drug sales revenues for simvastatin

Recent Clinical Trials for simvastatin

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Cancer Institute, Naples	PHASE2
Chang Gung Memorial Hospital	NA
Post Graduate Institute of Medical Education and Research, Chandigarh	NA

See all simvastatin clinical trials

Generic filers with tentative approvals for SIMVASTATIN

Applicant	Application No.	Strength	Dosage Form
		20MG	TABLET; ORAL
		10MG	TABLET; ORAL
		5MG	TABLET; ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for simvastatin

Drug Class	HMG-CoA Reductase Inhibitor
Mechanism of Action	Hydroxymethylglutaryl-CoA Reductase Inhibitors

Medical Subject Heading (MeSH) Categories for simvastatin

Anticholesteremic Agents

Hydroxymethylglutaryl-CoA Reductase Inhibitors

Hypolipidemic Agents

Anatomical Therapeutic Chemical (ATC) Classes for simvastatin

C10AA	HMG CoA reductase inhibitors
C10A	LIPID MODIFYING AGENTS, PLAIN
C10	LIPID MODIFYING AGENTS
C	Cardiovascular system

US Patents and Regulatory Information for simvastatin

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Synthon Pharms	SIMVASTATIN	simvastatin	TABLET, ORALLY DISINTEGRATING;ORAL	021961-003	Oct 9, 2007		DISCN	Yes	No
Accord Hlthcare	SIMVASTATIN	simvastatin	TABLET;ORAL	078155-003	Feb 26, 2008	AB	RX	No	No
Watson Labs Teva	SIMVASTATIN	simvastatin	TABLET;ORAL	076685-002	Dec 20, 2006		DISCN	No	No
Chartwell Rx	SIMVASTATIN	simvastatin	TABLET;ORAL	077766-005	Dec 20, 2006		DISCN	No	No
Biocon Pharma	SIMVASTATIN	simvastatin	TABLET;ORAL	078034-001	Dec 20, 2006	AB	RX	No	No
Aurobindo Pharma	SIMVASTATIN	simvastatin	TABLET;ORAL	077691-003	Dec 20, 2006	AB	RX	No	No

International Patents for simvastatin

Country	Patent Number	Title	Estimated Expiration
Austria	E552825
Australia	2007245410	Liquid oral compositions
China	101431982	Liquid oral compositions
Cyprus	1112917
Denmark	2018153
European Patent Office	2018153	COMPOSITIONS ORALES LIQUIDES (LIQUID ORAL COMPOSITIONS)

Supplementary Protection Certificates for simvastatin

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0720599	C300172	Netherlands		PRODUCT NAME: EZETIMIBE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN SIMVASTATINE; NAT. REGISTRATION NO/DATE: RVG 30927RVG 30928RVG 30929RVG 30930 2004221122; FIRST REGISTRATION: 58874.00.0058874.01.0058874.02.0058874.03.0058878.00.0058878.01.0058878.02.0058878.03.0058866.00.0058866.01.0058866.02.0058866.03.0058870.00.0058870.01.0058870.02.0058870.03.00 2004020402
0720599	26/2005	Austria		PRODUCT NAME: EZETIMIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON KOMBINIERT MIT SIMVASTATIN; NAT. REGISTRATION NO/DATE: 1-25673 - 1-25676 20041228; FIRST REGISTRATION: DE 58874.00.00 - 58874.03.00; 58878.00.00 - 20040402
0720599	122004000026	Germany		PRODUCT NAME: EZETIMIB ODER PHARMAZEUTISCH ANNEHMBARE SALZE DAVON IN KOMBINATION MIT SIMVASTATIN; NAT. REGISTRATION NO/DATE: 58866.00.00 58866.01.00 58866.02.00 58866.03.00 58870.00.00 58870.01.00 58870.02.00 58870.03.00 58874.00.00 58874.01.00 58874.02.00 58874.03.00 58878.00.00 58878.01.00 58878.02.00 58878.03.00 20040402 FIRST REGISTRATION: DE 58866.00.00 - 58866.03.00 58870.00.00 - 58870.03.00 58874.00.00 - 58874.03.00 58878.00.00 - 58878.03.00 20040402
0720599	05C0040	France		PRODUCT NAME: EZETIMIBE; SIMVASTATINE; NAT. REGISTRATION NO/DATE: NL 31849 20050728; FIRST REGISTRATION: DE - 58 878 00 00 20040402
0720599	SPC/GB05/010	United Kingdom		PRODUCT NAME: EZETIMIBE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF IN COMBINATION WITH SIMVASTATIN; REGISTERED: DE 58874.00.00 20040402; DE 58874.01.00 20040402; DE 58874.02.00 20040402; DE 58874.03.00 20040402; DE 58878.00.00 20040402; DE 58878.01.00 20040402; DE 58878.02.00 20040402; DE 58878.03.00 20040402; DE 58866.00.00 20040402; DE 58866.01.00 20040402; DE 58866.02.00 20040402; DE 58866.03.00 20040402; DE 58870.00.00 20040402; DE 58870.01.00 20040402; DE 58870.02.00 20040402; DE 58870.03.00 20040402; UK PL 19945/0003 20041118; UK PL 19945/0004 20041118; UK PL 19945/0005 20041118; UK PL 19945/0006 20041118; UK PL 19945/0007 20041118; UK PL 19945/0008 20041118; UK PL 19945/0009 200411

Simvastatin Market Dynamics and Financial Trajectory: Volume, Pricing, Competitive Pressures, and Key Patent/Exclusivity Signals

Last updated: June 12, 2026

Simvastatin is a mature, high-volume statin with extensive generic availability in the US and most major markets. The financial trajectory is dominated by (1) generic price compression, (2) periodic safety-driven labeling and formulation adjustments that shift share within the statin class, and (3) ongoing substitution toward other statins where clinical or formulary dynamics support it. In the long run, growth is constrained by generic penetration, but the absolute market value remains large due to persistent cardiovascular use.

---

H2: How big is the global simvastatin market and how has it trended financially?

Featured snippet: Simvastatin remains a large statin market by volume, but financial growth is modest because pricing falls persistently after generic entry across regions.

Market shape: volume-first, value-second

• Simvastatin’s unit demand stays resilient because it is entrenched in formularies for hyperlipidemia and cardiovascular risk reduction.
• Value is structurally volatile due to:
  • generic erosion after each wave of patent and exclusivity expiry,
  • tendering and contract pricing in government and payer channels,
  • cross-border parallel trade in some jurisdictions.

Pricing pressure mechanics

• Once multiple generics participate, wholesale acquisition costs reset downward, with:
  • rapid declines in early generic months,
  • slower “flooring” driven by manufacturing cost curves and market exit risk.
• Basket substitution within statins influences effective pricing:
  • when a low-cost generic of a competitor (e.g., atorvastatin or rosuvastatin) becomes the payer default, simvastatin shares shift and price can be pressured again.

Financial trajectory implications for investors and licensors

• Revenue growth for incumbents is unlikely; total market value tracks mainly with population and adherence, not price.
• For companies with strong manufacturing and low-cost supply, cash flows can remain stable despite margin compression because scale offsets price erosion.

---

H2: What market dynamics drive simvastatin demand and share versus other statins (atorvastatin, rosuvastatin)?

Featured snippet: Demand is durable, but share migrates based on payer formularies, guideline implementation, and clinical perceptions around potency and safety profiles across statins.

Key competitive drivers

1. Formulary tiering

   • Payers commonly place one or two statins as preferred options based on negotiated rebates and tender results.
   • Simvastatin often competes as a low-cost “baseline” option, but it can lose share if rosuvastatin or atorvastatin is placed as the preferred statin.

2. Dose intensity and LDL-C reduction needs

   • Clinicians select higher potency when targets are aggressive.
   • This can tilt relative share toward atorvastatin/rosuvastatin, especially in populations requiring substantial LDL-C lowering.

3. Safety and tolerability discussions

   • Muscle symptom risk and drug-drug interaction concerns affect prescriber behavior.
   • Simvastatin’s interaction profile (CYP3A4 mediated) can influence selection in patients on complex regimens.

4. Generic supply and contracting

   • Markets often consolidate on a limited number of suppliers.
   • Simvastatin stays in play for generic tenders, so supply strength can preserve access even as competitors gain preference.

---

H2: What is simvastatin’s exclusivity timeline and when did generic competition accelerate?

Featured snippet: Simvastatin’s original brand exclusivity is long expired in the US, which is why generic price compression is persistent rather than episodic.

US exclusivity and patent-era dynamics

• Simvastatin is an established molecule first marketed in the late 1980s.
• The US has long since transitioned to widespread generic availability, meaning exclusivity no longer governs current economics.
• Remaining legal leverage, if any, typically comes from secondary patents and formulation or method-of-use claims rather than active ingredient composition.

How this shapes the financial trajectory

• The financial profile is a “settled” generic market:
  • no brand-level pricing power,
  • competition cycles driven by supplier entry/exit, quality issues, and contracting.

---

H2: What patents protect simvastatin today, and do they affect commercialization economics?

Featured snippet: With the active ingredient long out of primary patent, patent impact is mostly limited to specific brands’ secondary claims and specific dosage forms or labeling-linked use cases, not broad molecule freedom-to-operate.

Secondary patent categories that can still matter

• Formulation patents
  • controlled release, bioavailability optimization, or specific dosage technologies.
• Method-of-use patents
  • narrower claims tied to subpopulations or endpoints.
• Manufacturing process patents
  • can affect cost-of-goods for certain suppliers but rarely preserve premium pricing.

Practical commercialization impact

• Secondary patent estates usually affect:
  • launch timing for a particular competitor’s brand-like version,
  • litigation risk allocation during generic entry,
  • not the overall market pricing floor, which is driven by the largest-scale generics.

---

H2: What is the Orange Book status of simvastatin, and what does that mean for new generic entry risk?

Featured snippet: Orange Book listings for simvastatin reflect multiple generic ANDAs and, in some cases, listed patents for legacy products; for new entrants, key risk is usually patent litigation or labeling carveouts rather than active ingredient blocking.

Generic entry risk framework (in this category)

• For established generics, FDA approval is typically routine if patents are not listed for the ANDA-relevant reference listed drug (RLD) or if listed patents are handled via Paragraph IV certifications and litigation outcomes.
• In a mature generic market:
  • the commercial outcome is often determined more by supplier economics than by regulatory delay.

---

H2: What patent litigation has shaped simvastatin commercialization, including settlements and launch timing?

Featured snippet: Simvastatin is largely governed by historical litigation and generic settlement cycles from earlier eras; today’s economics are driven more by contract pricing and manufacturing scale than by ongoing high-impact patent fights.

Where litigation still shows up

• Litigation risk typically affects:
  • availability of certain label claims,
  • timing of specific product launches (strengths, dosage forms, or combination packages),
  • and supply continuity if a manufacturer exits or faces remediation.

Economic linkage

• In a market where multiple suppliers already exist, even delays of a few months usually shift share within a narrow range, not restart market growth.

---

H2: What formulations and strengths are commercially dominant for simvastatin, and do they shift revenue?

Featured snippet: Tablet strengths and standard oral formulations drive volume; revenue shifts are mostly payer- and tender-led rather than technology-led.

Strength-by-strength market behavior (general pattern)

• Higher-liquidity strengths tend to be those most used in common titration pathways.
• When a payer specifies a strength or preferred brand/generic, procurement concentrates there, affecting revenue for manufacturers aligned with the tender.

Formulation relevance

• For simvastatin, formulation changes rarely create a premium market in the way they might for newer drugs.
• The main commercial impact is stability, manufacturability, and cost.

---

H2: How much revenue exposure do large pharma and generics have from simvastatin, and is it strategically important?

Featured snippet: Simvastatin is strategically more important as a high-volume generic cash-flow line than as a growth driver.

Who holds revenue exposure

• Generics: major share of sales value due to volume.
• Originator/brand-linked products: limited exposure due to generic substitution.
• Some pharma companies keep simvastatin in portfolios for:
  • broad SKU coverage,
  • payer relationship stability,
  • manufacturing utilization efficiency.

Strategic significance

• For diversified generic platforms, simvastatin supports:
  • baseline earnings,
  • bargaining leverage with wholesalers and pharmacy chains via scale.
• For brand-focused companies, it is typically not a central R&D or commercialization pillar due to lack of pricing power.

---

H2: What generic entry scenarios could still disrupt simvastatin pricing or supply?

Featured snippet: Disruption risk is less about molecule entry and more about supply consolidation, manufacturing quality events, and tender re-awards.

Scenario mapping

• Supplier exit or quality disruption
  • can cause localized shortages that temporarily raise prices.
• New low-cost entrant
  • can compress margins even in a commoditized market.
• Tender renegotiation
  • can reallocate share quickly across distributors and retail networks.
• Regulatory action
  • can narrow the active supplier set, affecting availability and contract economics.

---

H2: Are biosimilars relevant to simvastatin competition or substitution?

Featured snippet: No. Simvastatin is a small-molecule drug; biosimilar frameworks do not apply.

Competitive substitution is within small molecules

• Simvastatin’s direct competitive set is other oral statins.
• The key “swap” decisions are potency, safety interaction management, and payer formulary preference.

---

H2: How does simvastatin’s safety profile and drug-drug interaction risk influence prescribing and market share?

Featured snippet: Interaction risk with CYP3A4 inhibitors and muscle-related adverse event concerns influence prescriber behavior and can drive statin switching.

Commercially relevant safety dynamics

• Patients with polypharmacy are more likely to be switched toward statins with different metabolism profiles when clinicians aim to reduce interaction risk.
• This can create periodic share shifts inside the statin class even when overall statin demand remains stable.

---

H2: What do the regulatory and reimbursement dynamics imply for long-term financial trajectory?

Featured snippet: Reimbursement is the dominant long-term financial driver; clinical activity sustains volume, but reimbursement governs price and margin.

US channel dynamics (typical for mature generics)

• Retail: competitive contracting and pharmacy benefit manager preferences.
• Mail order: tenders and PBM tiering.
• Medicaid and government programs: procurement rules drive low-cost dominance.

Global dynamics

• Regions with tighter price caps can lock value down.
• Regions with less centralized tendering may show slower price erosion and more supplier-specific variability.

---

H2: How does simvastatin compare with atorvastatin and rosuvastatin on commercial economics?

Featured snippet: Simvastatin typically trades lower pricing for higher commoditization; atorvastatin and rosuvastatin can retain more payer preference based on perceived potency and formulary anchoring, even after generics arrive.

Comparative market mechanics

Driver	Simvastatin	Atorvastatin	Rosuvastatin
Competitive set	Primarily other statins	Same	Same
Pricing power	Low (high generic saturation)	Often low to moderate depending on payer deals	Often low to moderate
Share sensitivity	High to PBM/tender selection	High to formulary preference	High to potency-driven prescribing
Interaction considerations	CYP3A4 mediated interactions influence switching	Different interaction pattern	Different interaction pattern

---

H2: What are the key takeaways on simvastatin’s market trajectory for licensing, investment, or litigation planning?

Featured snippet: Treat simvastatin as a cash-flow market with pricing compression; legal and regulatory events rarely restore premium economics at the molecule level.

Key points

• Simvastatin’s financial trajectory is dominated by generic saturation and procurement pricing.
• Volume is stable; value grows slowly and mainly tracks adherence and population, not price.
• Patent leverage is limited to secondary patents for specific products, so the main commercialization battlefield is contracting and manufacturing economics.
• Competitive motion comes from within-class substitution, especially when payers favor higher potency statins.

---

Key Takeaways

• Simvastatin is a mature, high-volume small-molecule with persistent price compression and limited brand-like economic upside.
• Market value is driven by payer and tender economics; supplier scale and unit cost determine margin survival.
• Competitive share shifts occur mainly versus other oral statins based on formulary preference, LDL-C target practices, and prescriber sensitivity to drug-drug interactions.
• Patent and Orange Book dynamics today are primarily secondary and typically do not create broad, molecule-level exclusivity windows.

---

FAQs

1. Which statins are the closest commercial substitutes for simvastatin in payer formularies?
2. How do PBM formulary changes affect simvastatin generic share and pricing within retail and mail channels?
3. What manufacturing and quality factors most affect simvastatin supply availability and short-term pricing?
4. Do secondary patents for simvastatin dosage forms or labeling claims meaningfully delay generic competition today?
5. How do clinical guideline updates on LDL-C targets shift market share between simvastatin and higher-potency statins?

---

References (APA)

No sources were provided in the prompt, and no citations can be added without verifiable documents.